The Peptide Dispatch is an educational publication, not a clinic, pharmacy or vendor. This page explains where our information comes from, how we label it, and how we fix mistakes.
Last updated: October 1, 2026
Who we are
The Peptide Dispatch is written and maintained by The Peptide Dispatch Editorial Team. Pages show "Reviewed by The Peptide Dispatch Editorial Team"; we do not currently list a named medical reviewer.
The Peptide Dispatch and the 1836 Wellness clinic in Houston, Texas are both owned by 1836 Wellness LLC. That means we may benefit financially if a reader becomes a 1836 Wellness client, so we put a disclosure next to every link to 1836 Wellness.
No vendor, clinic or manufacturer, including 1836 Wellness, pays for coverage, reviews drafts before publication, or controls our conclusions. What we publish about a peptide is set by the evidence, not by whether anyone offers it.
Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Sources we use, in order of weight
FDA drug labels and regulatory documents: what a drug is approved for, its label warnings and side effects, and its legal status.
Human clinical trials: randomized trials first, then smaller or uncontrolled human studies.
Animal and lab studies: rodent, cell-culture and ex vivo work. Useful for how something might work, but not proof that it works in people.
Community and user reports: what people in user communities say they do and experience. Always labeled as community-reported, never presented as study data.
The three evidence labels
Points on profiles and comparison pages carry a label that says where they come from:
Clinicalhuman trials and FDA labels. Example (Semaglutide profile): “In clinical use (FDA label, Ozempic): the most common adverse reactions are nausea, vomiting, diarrhea, abdominal pain and constipation”
Lab / animalrodent, cell and ex vivo studies. Example (Selank profile): “In rats under chronic mild stress: enhanced the anxiety-reducing effect of diazepam (Kasian 2017)”
Community-reporteduser experience and commonly used protocols, not from clinical studies. Example (BPC-157 profile): “Some users report running BPC-157 at 250–500 mcg (subcutaneous injection).”
Community content
We report what users say and do. We never recommend a dose, a protocol or a product.
Community reports are anecdotal. Results vary with product quality and purity, which is often unknown for products sold outside pharmacies.
Community content comes only from our own records of what user communities report. We don't add doses, durations or effects to make a sentence read better.
When published research contradicts a community claim, we keep the claim visible with a research note saying the study did not confirm it.
What we don't do
No dosing recommendations. "Dosing used in published research" describes what a study gave its subjects; "Community-reported" doses describe what users report.
No selling peptides. We are not a vendor, pharmacy or prescriber.
No vendor affiliate links on profiles. The only commercial links are to our commonly owned clinic, 1836 Wellness, and each one carries the disclosure.
How often we update
Every profile shows a "Last reviewed" date that changes when its content changes.
The FDA Peptide Compounding Status Tracker (/regulatory) is re-verified whenever FDA or its advisory committee acts, and shows its own "Last verified" date and changelog.
Corrections are welcome. If you spot an error, contact us and we'll check it against the sources.
66 profiles re-checked against PubMed. Every profile now lists its references: 179 PubMed-indexed papers in total, each with PubMed and DOI links.
7 duplicate or stray profiles merged into their main pages, with permanent redirects from the old addresses.
Effect bullets now say what kind of study they come from; 43 bullets that no verified paper supported were removed.
55 mechanism descriptions rewritten to say what kind of study they come from. One mechanism paper (Dihexa, Benoist 2014) was found to have been retracted in 2025, and the profile now says so.
Notes meant for editors were removed from published text.
Regulatory notes for the peptides the FDA advisory committee voted on were aligned with sourced wording, and the FDA Peptide Compounding Status Tracker was published at /regulatory.
Clinical, Lab / animal and Community-reported labels and "What Users Report" sections were added. Side effects shown for semaglutide, tirzepatide and dulaglutide were checked against their current FDA labels.